Abstract Introduction: The American Thyroid Association appointed a Task Force of experts
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …

Background: Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and
challenging malignancy. The American Thyroid association (ATA) chose to create specific …

Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …

Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor
(VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib …

Background Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib)
in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement …

Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and
parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal …

Answer questions and earn CME/CNE Thyroid cancer exists in several forms. Differentiated
thyroid cancers include those with papillary and follicular histologies. These tumors exist …

Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN)
type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has …

Purpose There is no effective therapy for patients with distant metastasis of medullary thyroid
carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC …